Glucagon-like peptide-1 (GLP-1), secreted from gut L cells upon nutrient intake, forms the basis for novel drugs against
type 2 diabetes (T2D). Secretion of
GLP-1 has been suggested to be impaired in T2D and in conditions associated with
hyperlipidemia and
insulin resistance. Further, recent studies support lipotoxicity of GLP-1-producing cells in vitro. However, little is known about the regulation of L-cell viability/function, the effects of
insulin signaling, or the potential effects of stable
GLP-1 analogs and dipeptidyl peptidase-4 (DPP-4) inhibitors. We determined effects of
insulin as well as possible autocrine action of
GLP-1 on viability/apoptosis of GLP-1-secreting cells in the presence/absence of
palmitate, while also assessing direct effects on function. The studies were performed using the GLP-1-secreting cell line GLUTag, and
palmitate was used to simulate
hyperlipidemia. Our results show that
palmitate induced production of
reactive oxygen species and
caspase-3 activity and reduced cell viability are significantly attenuated by preincubation with
insulin/
exendin-4. The indicated lipoprotective effect of
insulin/
exendin-4 was not detectable in the presence of the
GLP-1 receptor (GLP-1R) antagonist
exendin (9-39) and attenuated in response to pharmacological inhibition of exchange
protein activated by cAMP (
Epac) signaling, while
protein kinase A inhibition had no significant effect.
Insulin/
exendin-4 also significantly stimulate acute and long-term
GLP-1 secretion in the presence of
glucose, suggesting novel beneficial effects of
insulin signaling and GLP-1R activation on glycemia through enhanced mass of GLP-1-producing cells and enhanced
GLP-1 secretion. In addition, the effects of
insulin indicate that not only is
GLP-1 important for insulin secretion but altered
insulin signaling may contribute to an altered
GLP-1 secretion.